Pfizer scored an accelerated approval Friday to bring its BRAF inhibitor to first-line colorectal cancer patients.

Eli Lilly dominates obesity market, megadeals decline, I&I sector thrives, and FDA's setback in misinformation fight.

Aadi Bioscience sells cancer drug Fyarro to Kaken Pharmaceutical for $100M, licenses three ADCs from WuXi Biologics and ...

Applied Therapeutics CEO Shendelman exits; CFO Funtleyder becomes interim CEO after FDA rejects govorestat. Company withdraws ...

→ Yu­ki Abe will step in to re­place the late Toshi­nori Agat­suma on Jan. 1 as head of … Get free access to a limited number ...

House Speaker Johnson and GOP push for narrow spending bill without healthcare reforms as midnight shutdown deadline looms; ...

FDA approves Ionis' olezarsen as first treatment for familial chylomicronemia syndrome. Arrowhead's plozasiran pending FDA ...

Rhythm Pharmaceuticals received FDA approval to market its genetic obesity drug Imcivree for children as young as 2 years old ...

Syncromune, a biotech startup working on combination immunotherapies, has put together a $100 million Series A, the company ...

The FDA rejected Zealand Pharma’s short bowel syndrome drug, and asked the company to run another trial before it reconsiders ...

The Institute for Clinical and Economic Review said major insurers’ drug coverage policies generally do align with the ...

The AI-focused biotech insitro is advancing a new idea to potentially treat ALS, one of the most intractable and brutal ...